CD47 and neoplasm: Recent studies demonstrated that bispecific antibody or fusion protein against both PD‐L1 and CD47 showing better tumour‐cell targeting and stronger therapeutic effect than those of single blockade (Chen, Dominik, et al., 2021; Liu, Liu, et al., 2018).